Mesoblast (ASX:MSB) share price jumps 19% on FDA update

The Mesoblast limited (ASX:MSB) share price is racing higher on Wednesday after the US FDA granted it a fast track designation for COVID-19 ARDS…

| More on:
high share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast limited (ASX: MSB) share price has started the day strongly and is racing materially higher.

At the time of writing, the biotechnology company's shares are up 12% to $4.62. But at one stage they were up as much as 19% to $4.90.

Why is the Mesoblast share price racing higher?

Investors have been buying the company's shares this morning after the release of a positive announcement relating to its remestemcel-L product.

According to the release, the United States Food and Drug Administration (FDA) has granted Fast Track designation for remestemcel-L in the treatment of acute respiratory distress syndrome (ARDS) due to COVID-19 infection.

Fast Track designation is granted if a therapy demonstrates the potential to address unmet medical needs for a serious or life-threatening disease. Given that ARDS is the primary cause of death in patients with COVID-19, it wasn't a surprise to see the FDA grant it this designation.

The company notes that the clinical data provided to the FDA included results from a pilot study of remestemcel-L under emergency compassionate use at New York's Mt Sinai Hospital in March-April this year.

In this study, nine of 12 ventilator-dependent patients with moderate to severe COVID-19 ARDS were successfully discharged from hospital a median of 10 days after receiving two intravenous doses of remestemcel-L.

A larger phase 3 trial with up to 300 ventilator-dependent patients is ongoing and is approximately two-thirds enrolled.

Two interim analyses have been performed by the independent Data Safety Monitoring Board (DSMB), after 90 and 135 patients were enrolled. Following this analysis, the DSMB recommended that the trial continue as planned.

A third and final interim analysis is planned to be performed by the DSMB when 180 patients have completed 30 days of follow-up.

One company which appears optimistic on the treatment is Novartis. The two parties recently entered into a license and collaboration agreement for the development, manufacture, and commercialisation of remestemcel-L, with an initial focus on the treatment of ARDS, including COVID-19 ARDS.

The deal saw Novartis pay US$50 million up front and agree to pay upwards of US$1.25 billion in milestone payments depending on its success.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors ended up snatching defeat from the jaws of victory today.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Share Gainers

Why Clarity, Omni Bridgeway, Santana Minerals, and Vulcan shares are pushing higher today

These shares are having a good time on hump day. But why?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 44%

Investors are sending the ASX All Ords stock racing higher today. But why?

Read more »

A young boy wearing a hat, sunnies and striped singlet looks fierce and flexes his arm in victory.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares finally caught a break this Tuesday.

Read more »

three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
Share Gainers

Why Novonix, PEXA, Tamboran Resources, and Westgold shares are storming higher

These shares are having a good time on Tuesday. Let's find out what's happening.

Read more »

Silhouettes of nine people climbing a steep mountain to the top at sunset, and helping each other along the way.
Share Gainers

Here are the top 10 ASX 200 shares today

The markets endured a rough start to the week this Monday.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why 4DMedical, Brainchip, Meridian, and SCEE shares are rising today

These shares are having a strong start to the week. But why?

Read more »

A man wearing a red jacket and mountain hiking clothes stands at the top of a mountain peak and looks out over countless mountain ranges.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares had a rough end to the trading week this Friday.

Read more »